Match!
Tracy Merlin
University of Adelaide
72Publications
17H-index
1,268Citations
Publications 72
Newest
Published on Aug 30, 2019in Genetics in Medicine8.68
Sharon Kessels1
Estimated H-index: 1
(University of Adelaide),
Drew Carter6
Estimated H-index: 6
(University of Adelaide)
+ 2 AuthorsTracy Merlin17
Estimated H-index: 17
(University of Adelaide)
We aimed to assess the clinical value of prenatal testing for cystic fibrosis (CF) and whether ethical considerations would affect endpoint selection. To determine effectiveness, we conducted a systematic literature review whose protocol outlined search strategies across eight databases, study inclusion criteria, and prespecified literature screening, data extraction, and synthesis processes. We conducted a scoping search on ethical considerations. The genetic test showed good diagnostic perform...
Published on May 1, 2019in Value in Health5.04
Drew Carter6
Estimated H-index: 6
,
Tracy Merlin17
Estimated H-index: 17
+ 0 AuthorsDavid Hunter
Abstract Sometimes a government or other payer is called on to fund a new health technology even when the evidence leaves a lot of uncertainty. One option is for the payer to provisionally fund the technology and reduce uncertainty by developing evidence. This is called coverage with evidence development (CED). Only-in-research CED, when the payer funds the technology only for patients who participate in the evidence development, raises the sharpest ethical questions. Is the patient coerced or i...
Published on Jan 1, 2019in Australian Health Review1.23
Nadine T. Hillock , Lisa Paradiso + 2 AuthorsTracy Merlin17
Estimated H-index: 17
Objective Increasing antimicrobial resistance and a concurrent paucity of new antimicrobials marketed increases the risk that patients will develop infections resistant to currently available drugs. This study aimed to determine the range of clinical indications for which unregistered antimicrobials are prescribed at two tertiary hospitals in South Australia to identify any trends over a 2-year period. The effects of recent regulatory changes to the Special Access Scheme (SAS) were assessed. Met...
Published on Dec 1, 2018in Health Research Policy and Systems2.22
Tracy Merlin17
Estimated H-index: 17
(University of Adelaide)
Decisions regarding the regulation of individual medicines differ from country to country. In the case of Relenza, Mulinari and Davis (Health Res Policy Syst 15:93, 2017) have suggested that these inconsistencies are primarily due to processes, statistical methodologies and technical capacity varying between regulatory agencies. They go on to name specific individuals involved in the evaluation of this anti-influenza medicine and imply that differences in the judgements of these individuals has ...
Published on Oct 1, 2018in Medical Decision Making2.79
Michelle Maria Aleida Kip5
Estimated H-index: 5
(UT: University of Twente),
Maarten Joost IJzerman39
Estimated H-index: 39
(UT: University of Twente)
+ 5 AuthorsHendrik Koffijberg22
Estimated H-index: 22
(UT: University of Twente)
Objectives. General frameworks for conducting and reporting health economic evaluations are available but not specific enough to cover the intricacies of the evaluation of diagnostic tests and biomarkers. Such evaluations are typically complex and model-based because tests primarily affect health outcomes indirectly and real-world data on health outcomes are often lacking. Moreover, not all aspects relevant to the evaluation of a diagnostic test may be known and explicitly considered for inclusi...
Published on Aug 1, 2018in Value in Health5.04
Shuhong Wang3
Estimated H-index: 3
(University of Adelaide),
Debra Gum1
Estimated H-index: 1
(University of Adelaide),
Tracy Merlin17
Estimated H-index: 17
(University of Adelaide)
Abstract Objectives The English National Institute for Health and Care Excellence (NICE) and the Australian Pharmaceutical Benefits Advisory Committee (PBAC) require evidence that a new medicine represents value for money before being publicly funded. NICE has an explicit threshold for cost effectiveness, whereas PBAC does not. We compared the initial incremental cost-effectiveness ratios (ICERs) presented by manufacturers in matched submissions to each decision-making body, with the aim of expl...
Published on Jul 1, 2018in Appetite3.50
Adyya Gupta7
Estimated H-index: 7
(University of Adelaide),
Lisa G. Smithers20
Estimated H-index: 20
(University of Adelaide)
+ 2 AuthorsAnnette J Braunack-Mayer22
Estimated H-index: 22
(University of Adelaide)
Abstract Efforts to reduce sugar intake levels have been primarily limited to increasing knowledge and changing attitudes. We conducted a systematic review to (1) identify factors influencing adults' knowledge and attitudes about sugar, and (2) determine if there is an association between knowledge and attitudes about sugar and sugar intake. We searched 15 electronic databases from inception to December 2016 for English language publications including adults with relevant exposure and outcome me...
12345678